Brief: Ryvu Therapeutics Says FDA Lifts Partial Clinical Hold On Rvu120 Phase Ib Study In Acute Myeloid Leukemia And Myelodysplastic Syndrome
14/07/2021 13:40
July 14 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* FDA LIFTS PARTIAL CLINICAL HOLD ON RVU120 (SEL120) PHASE
IB
STUDY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
Source text for Eikon: ID:nEM4kRkVpa
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys